Phase II trial of Endostar combined with CHOPT for T cell lymphoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-11001598

Enrollment

Unknown

Registered

2011-05-22

Start date

2011-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T cell lymphoma

Interventions

1:Endostar combined with CHOPT regime

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 70 years old; 2. Diagnosis of T cell lymphoma according to WHO Classification, without antitumor therapy; 3. At least 1 measurable tumor mass (greater than 1.5cm in the longest dimension and greater than 1.0 in the short axis); 4. Eastern Cooperative Oncology Group status 0-2; 5. White blood cell>=4.0*10^9cells/L; Absolute neutophil count (ANC) >=1.5*10^9cells /L; Platelets>=100*10^9cells/L; 6. Alanine transaminase (ALT) <=2*upper limit of normal(ULN); Aspartate transaminase (AST) <=2*ULN; Total Bilirubin<=1.5*ULN; Creatinine in normal range.

Exclusion criteria

Exclusion criteria: 1. No active central nervous system lymphoma or brain tumor; 2. Supperative inflammation,Chronic infection; 3. Severious heart disease, conclusion: congestive heart failure; uncontrolled cardiac arrhythmia; myocardial infarction; refractory hypertension; 4. Psychiatric history; 5. Primary cutaneous T cell lymphoma; 6. Pregnant or lactating women; 7. Concurrent treatment with another investigational agent; 8. Accept radiotherapy.

Design outcomes

Primary

Measure	Time frame
Survival;VEGF concentration;	—

Countries

China

Contacts

Public ContactHuaqing Wang

Tianjin Medical University Cancer Institute and Hospital

huaqingw@163.com+86 022-23340123-2601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026